



(11) **EP 1 110 541 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
27.06.2001 Bulletin 2001/26

(51) Int Cl.7: **A61K 9/19**

(21) Application number: **00311631.6**

(22) Date of filing: **22.12.2000**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

- **Wearley, Lorraine L.**
Westfield, NJ 07090 (US)
- **Gole, Dilip J.**
Plainsboro, NJ 08536 (US)
- **Posage, Gary W.**
New Hope, Pennsylvania 18938 (US)
- **Wilkinson, Paul K.**
Doylestown, Pennsylvania 18901 (US)

(30) Priority: **23.12.1999 US 471825**

(71) Applicant: **JOHNSON & JOHNSON CONSUMER**
COMPANIES, INC.
Skillman, NJ 08558 (US)

(74) Representative: **Fisher, Adrian John**
CARPMAELS & RANSFORD
43 Bloomsbury Square
London WC1A 2RA (GB)

(72) Inventors:
• **Lin, Shun Y**
Plainsboro, NJ 08536 (US)

(54) **Controlled release composition comprising a sustained release layer and a fast release layer**

(57) The present invention provides a composition comprising a sustained release layer and a fast release layer. The sustained release layer comprises a water-soluble polymer and a first pharmaceutically active agent. The fast release layer comprises a matrix forming agent and a second pharmaceutically active agent.

Generally, the composition provides fast and sustained (or controlled) release of a pharmaceutically active agent for at least 6 hours and preferably for at least 1 to 3 days. The composition may be incorporated into a dosage unit form, such as a vaginal insert. The compositions are prepared by freeze-drying.

EP 1 110 541 A1

Description**FIELD OF THE INVENTION**

- 5 [0001] The present invention relates to a composition which provides fast and sustained delivery of a pharmaceutically active agent. The present invention also relates to methods of preparing the same.

BACKGROUND OF THE INVENTION

- 10 [0002] Freeze-drying, also known as lyophilization, is a well-known method of drying heat-sensitive materials in order to increase product stability and shelf life. Products containing active ingredients, such as pharmaceuticals, nutrients, diagnostics, fertilizers, and insecticides are frequently prepared by freeze-drying aqueous solutions or suspensions containing these active ingredients. Generally, freeze-drying involves freezing a material and then sublimating it under high vacuum.

- 15 [0003] Conventional freeze-drying processes often cause cracking of the freeze-dried preparation and meltback. Cracking typically is caused by stresses during ice crystallization. Meltback occurs when the heat required for drying melts the frozen material, defeating the purpose of the freeze-drying process. Meltback can result in interfacial penetration of layers in multi-layered dosage forms. To avoid both cracking and meltback during freeze-drying, small amounts of material of limited thickness are typically dried at one time or, alternatively, at very low temperatures. Sublimation at very low temperatures, however, usually requires a relatively long period of time.

- 20 [0004] Freeze-drying methods generally yield products which disintegrate easily and are often sticky and crumbly when handled. Various freeze-drying and packaging methods have been employed in attempts to circumvent this problem. However, tablets produced by such methods usually are still susceptible to sticking and crumbling if transferred to other packaging.

- 25 [0005] Conventional freeze-drying methods also do not produce products which have uniform porosity. Uniform porosity in a freeze-dried product is important for controlling the release of active agents from the freeze-dried dosage form.

- [0006] In the area of pharmaceuticals, dosage forms which can provide a fast and sustained treatment are often of critical importance for patient's compliance, especially for patients using over-the-counter medicines. A dosage form with a fast release layer requires less time to reach the effective drug concentration in the target area than a conventional sustained release dosage form. A dosage form with a sustained release layer is designed to maintain a therapeutic drug concentration in the target area for relatively long periods of time. Presently, patients often have to be treated with two or more different dosage forms in order to obtain a fast and sustained therapeutic effect. Therefore, a single dosage form which provides a fast and sustained therapeutic effect would significantly improve patients' compliance.

- 35 [0007] Vaginal dosage forms such as creams, gels, suppositories, and ovules are well known in the art. These dosage forms, however, tend to spread out readily and often inadvertently discharge from the cavity, making such products inconvenient and messy to use. Thus, there is a need for a dosage form which provides both a fast and sustained therapeutic effect in target areas, more particularly, in areas such as vaginal cavity, where multi-dosing is inconvenient and messy.

40

SUMMARY OF THE INVENTION

- [0008] The present invention provides a composition comprising a sustained release layer and a fast release layer. The sustained release layer comprises a water-soluble polymer and a first pharmaceutically active agent. The fast release layer comprises a matrix forming agent and a second pharmaceutically active agent. Generally, the composition provides fast and sustained (or controlled) release of a pharmaceutically active agent for at least 6 hours and preferably for at least 1 to 3 days. The composition may be incorporated into a dosage unit form, such as a vaginal insert.

- 45 [0009] Another embodiment of the present invention is a method of preparing the aforementioned composition. The method comprises (a) preparing a first aqueous solution containing a water-soluble polymer and a first pharmaceutically active agent; (b) preparing a second aqueous solution containing a matrix forming agent and a second pharmaceutically active agent; (c) pouring the first and second aqueous solutions into a container; and (d) freeze-drying the solution in the container to produce the composition.

50

DETAILED DESCRIPTION OF THE INVENTION

55

- [0010] The composition of the present invention comprises a sustained release layer and a fast release layer. Generally, the composition provides fast and sustained (or controlled) release of a pharmaceutically active agent for at least 6 hours and preferably for at least 1 to 3 days. The composition is particularly useful as a vaginal insert for

treatment of vaginal diseases without multi-dosing.

[0011] The sustained release layer comprises a water-soluble polymer and a first pharmaceutically active agent. Suitable water soluble polymers include, but are not limited to, celluloses, cellulose ethers, or derivatives thereof, such as those disclosed in U.S. Patent No. 4,615,697 and polycarbophills; polycarboxylated vinyl polymers, such as polyacrylic acid polymers optionally crosslinked with polyalkenyl polyethers, such as, for example, Carbopol 434, Carbopol 934P, Carbopol 940, and Carbopol 941, all of which are available from B. F. Goodrich of Cincinnati, OH; polyurethanes; gelatins; polysaccharide gums, such as natural plant exudates, including, but not limited to, karaya gum and ghatti gum; seed gum, such as guar gum, locust bean gum, and psyllium seed gum; crosslinked alginate gum gel, such as those disclosed in U.S. Patent No. 3,640,741; and any combination of any of the foregoing. Preferred water-soluble polymers include, but are not limited to, polyurethanes, gelatins, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylcellulose, hydroxypropylethylcellulose, carbopol, polyvinyl alcohol and derivatives thereof, dextran, chitosan and derivatives thereof, starches and derivatives thereof, polyacrylamides, polyacrylates, agar, collagen, fibronectin, alginic acid, pectin, hyaluronic acid, and any combination of any of the foregoing. The matrix forming agent forms a matrix and aids in dispersing the pharmaceutically active agent in the layer.

[0012] The sustained release layer preferably includes a fatty acid or a mixture of fatty acids, such as a hydrogenated vegetable oil. The fatty acid accelerates disintegration of the layer and release of the pharmaceutically active agent. Preferred fatty acids melt at about body temperature. Two preferred hydrogenated vegetable oils are Wecobee FS™ and Wecobee M™ available from Stepan Company of Northfield, IL.

[0013] Suitable pharmaceutically active agents include, but are not limited to, anti-fungal agents, anti-bacterial agents, nutrients, vitamins, minerals, diagnostics, fertilizers, insecticides, and any combination of any of the foregoing. Other suitable pharmaceutically active agents include, but are not limited to, those which have a prophylactic purpose, such as prevention of pregnancy and sexually transmitted diseases. Preferred pharmaceutically active agents include, but are not limited to, metronidazole; terconazole; miconazole nitrate; chlorpheniramine maleate; pseudophedrine; detromethorphan; meclizine dihydrochloride; haloperidol; albuterol sulfate; dimenhydrinate; benzodiazepines, such as diazepam, lorazepam, and congeners thereof; and any combination of any of the foregoing. A more preferred pharmaceutically active agent is metronidazole. The pharmaceutically active agent may be coated with any coating agent known in the art. Preferably the pharmaceutically active agent is coated with a coating agent which protects it from solvents and other chemicals and environmental conditions which could dissolve or deteriorate the pharmaceutically active agent before reaching its intended target. The coating agent may also mask the flavor and/or odor of the pharmaceutically active agent. Suitable coating agents include, but are not limited to, fatty acids; glycerides, including, but not limited to, triglycerides; and any combination of any of the foregoing.

[0014] The sustained release layer generally comprises from about 5 to about 70% by weight, preferably from about 10 to about 50% by weight, and more preferably from about 10 to about 30% by weight of water-soluble polymer, based upon 100% total weight of sustained release layer.

[0015] The sustained release layer preferably comprises up to about 15% by weight and more preferably from about 5 to about 10% by weight of fatty acid, based upon 100% total weight of sustained release layer.

[0016] The weight ratio of fatty acid to water-soluble polymer preferably ranges from about 1:10 to about 3:5 and is more preferably about 2:5.

[0017] The sustained release layer generally comprises a therapeutic effective amount of pharmaceutically active agent. The sustained release layer preferably contains from about 15 to about 95% by weight and more preferably from about 50 to about 85% by weight of pharmaceutically active agent, based upon 100% total weight of sustained release layer.

[0018] The sustained release layer may include other adjuvants, such as preservatives, flavorants, antioxidants, surfactants, sweeteners, viscosity enhancers, colorants, fragrances, plasticizers, lubricants, fillers, binders, wetting agents, penetration agents, pH adjusters, disintegrants, excipients, or any combination of any of the foregoing. Since the water uptake of the sustained release layer is typically not significant, preservatives are generally not required to enhance the stability of the composition.

[0019] The sustained release layer is typically flexible and muco-adherent.

[0020] Generally, the sustained release layer provides a sustained release of a therapeutically effective amount of the first pharmaceutically active agent. Preferably, the sustained release layer provides a sustained release of the first pharmaceutically active agent for at least 6 hours and more preferably for at least about 1 to 3 days.

[0021] The fast release layer comprises a matrix forming agent and a second pharmaceutically active agent. Suitable matrix forming agents include, but are not limited to, animal and vegetable protein derivatives, such as gelatins, dextrans, soy, and wheat end psyllium seed proteins; gums, such as acacia, guar, agar, and xanthan; polysaccharides; alginates; carboxymethylcelluloses; carrageenans; dextrans; pectins; polyvinylpyrrolidones; polyacrylic acids; polypeptide/protein complexes, such as gelatin-acacia complexes; polypeptide/polysaccharide complexes; sugars, such as mannitol, dextrose, lactose, galactose, and cyclodextrin; inorganic salts, such as sodium phosphate, sodium chloride, and alu-

minum silicates; and amino acids having from about 2 to about 12 carbon atoms, such as glycine, L-alanine, L-aspartic acid, L-glutamic acid, L-hydroxyproline, L-isoleucine, and L-leucine, L-phenylalanine; and any combination of any of the foregoing. A preferred amino acid is glycine.

5 [0022] Preferably, the fast release layer comprises a gelatin, pectin, soy fiber protein, or a mixture thereof and an amino acid having from about 2 to about 12 carbon atoms. More preferably, the fast release layer comprises a gelatin, pectin, or a mixture thereof and an amino acid having from about 2 to about 12 carbon atoms.

[0023] The pharmaceutically active agent may be any of the aforementioned pharmaceutically active agents. The pharmaceutically active agent in the fast release layer may be the same or different than the pharmaceutically active agent in the sustained release layer.

10 [0024] The fast release layer generally comprises from about 0.5 to about 15% by weight, preferably from about 0.5 to about 10% by weight, and more preferably from about 4 to about 10% by weight of matrix forming agents, based upon 100% total weight of fast release layer. According to one preferred embodiment, the fast release layer comprises (A) from about 4 to about 8% by weight of a matrix forming agent and (B) from about 1 to about 20% by weight of an amino acid having from about 2 to about 12 carbon atoms, based upon 100% total weight of fast release layer.

15 [0025] The fast release layer generally comprises a therapeutic effective amount of pharmaceutically active agent. The fast release layer preferably contains from about 15 to about 95% by weight and more preferably from about 60 to about 90% by weight of pharmaceutically active agent, based upon 100% total weight of fast release layer.

[0026] According to a preferred embodiment, the fast release layer contains from about 4 to about 8% by weight of a matrix forming agent, from about 3 to about 5% by weight of at least one amino acid, and from about 2 to about 5% by weight of mannitol, based upon 100% total weight of fast release layer.

20 [0027] The fast release layer may include any of the aforementioned adjuvants.

[0028] Generally, the fast release layer provides fast release of the second pharmaceutically active agent. Preferably, the fast release layer releases a therapeutically effective amount of the second pharmaceutically active agent within about 4 minutes and more preferably within about 2 minutes.

25 [0029] The fast release layer may surround the sustained release layer. Also, both the fast release layer and the sustained release layer may be on the surface of the composition.

[0030] The density of the composition typically ranges from about 0.1 to about 0.5 g/cc. The dissolution rate of the composition generally ranges from about 1 to about 30 weight percent per hour, based upon 100% weight of composition.

30 [0031] Generally, the amount of pharmaceutically active agent in the composition is an amount effective to accomplish the purpose for which it is being used. The amount of pharmaceutically active agent is typically a pharmacologically or biologically effective amount. However, the amount can be less than a pharmaceutically or biologically effective amount when the composition is used in a dosage unit form because the dosage unit form may contain a multiplicity of compositions of the present invention or may contain a divided pharmacologically or biologically effective amount.

35 The total effective amount can then be determined in cumulative units containing, in total, a pharmacologically or biologically effective amount of the pharmaceutically active agent. The total amount of pharmaceutically active agent can be determined by those skilled in the art.

[0032] The composition may be incorporated into a dosage unit form, such as a vaginal insert. The vaginal insert may be administered digitally or with an applicator inside the vagina, preferably proximate to the cervix. The vaginal insert is typically completely and naturally soluble in the vagina. Since the vaginal insert is typically flexible and muco-adherent, the insert is comfortable to wear and generally does not prematurely discharge from the vagina. Furthermore, the muco-adherent properties of the composition enhance the drug-vaginal contact area and intravaginal retention. This results in increased delivery of the pharmaceutically active agent. The dosage unit form may be a non-aqueous cream, non-aqueous gel, suppository, or ovule.

45 [0033] The composition of the present invention may be prepared as follows. A water-soluble polymer and a first pharmaceutically active agent are added to water and mixed to form a first aqueous solution. The solution may also contain other water-miscible solvents. The solution generally contains from about 1 to about 20% by weight, preferably from about 2 to about 16% by weight, and more preferably from about 2 to about 7% by weight of a water-soluble polymer, based upon 100% weight of total solution. The solution also generally contains from about 1 to about 35% by weight and preferably from about 5 to about 25% by weight of a pharmaceutically active agent, based upon 100% weight of total solution. At concentrations below about 1% by weight of water-soluble polymer, the viscosity of the solution is typically very low, resulting in poor muco-adherent properties and uncontrolled release of the pharmaceutically active agent. A fatty acid and other adjuvants as described above may be added to the first aqueous solution. The solution preferably contains up to about 5% by weight and more preferably from about 1 to about 3% by weight of fatty acid, based upon 100% weight of total solution. Preferably, the solution is mixed to form a homogeneous mixture.

50 The pH of the mixture may be adjusted with a pH adjuster to optimize solubility and stability of the final composition. The solution preferably has a specific gravity ranging from about 1.0 to about 1.2 g/mL.

55 [0034] In a separate container, a matrix forming agent and a second pharmaceutically active agent are added to

water and mixed to form a second aqueous solution. The solution may also contain other water-miscible solvents. The matrix forming agent typically aids in dispersing the pharmaceutically active agent, especially when the pharmaceutically active agent is not water soluble. The second solution generally contains from about 0.1 to about 5% by weight, preferably from about 0.1 to about 3% by weight, and more preferably from about 1.5 to about 3% by weight of a matrix forming agent, based upon 100% weight of total solution. The second solution preferably contains from about 1 to about 35% by weight and more preferably from about 5 to about 25% by weight of a pharmaceutically active agent, based upon 100% weight of total solution.

[0035] According to one preferred embodiment, the second solution contains at least about 0.1% by weight of matrix forming agent, and an amino acid having from about 2 to about 12 carbon atoms, based upon 100% weight of total second solution. Preferably, the matrix forming agent is gelatin, pectin, soy fiber protein, or a mixture thereof. The amino acid is preferably glycine.

[0036] According to another preferred embodiment, the second solution contains from about 1.5 to about 2.5% by weight of a matrix forming agent and from about 0.5 to about 10% by weight of an amino acid having from about 2 to about 12 carbon atoms, based upon 100% weight of total second solution.

[0037] According to yet another preferred embodiment, the second solution contains from about 0.1 to about 3% by weight of matrix forming agent, from about 0.5 to about 10% by weight of one or more amino acids, and from about 0.5 to about 10% by weight of mannitol, based upon 100% weight of total second solution. More preferably, the second solution contains from about 1.5 to about 2.5% by weight of matrix forming agent, from about 1.4 to about 1.7% by weight of one or more amino acids, and from about 1.0 to about 1.5% by weight of mannitol, based upon 100% weight of total second solution.

[0038] The first and second aqueous solutions are poured into a container, such as a pre-shaped plastic cavity. According to one preferred embodiment, the first aqueous solution is poured into the container before the second aqueous solution is poured. According to another preferred embodiment, the weight ratio of the first solution to the second solution is about 1:1.

[0039] The solution in the container is then freeze-dried to form the composition. The solution may be freeze-dried by any method of freeze-drying known in the art. A preferred method of freeze-drying the solution comprises freezing the solution and lyophilizing the frozen solution. Freezing is preferably performed rapidly, such as with a cold gas freezing tunnel. The water in the frozen solution is then removed by lyophilization.

[0040] The following examples are intended to describe the present invention without limitation.

Examples 1-3

[0041] Fast release layers were prepared from each formulation shown in Table 1 as follows. Gelatin, mannitol, metronidazole, neutralized 0.5% carbopol gel, glycine, and xanthan gum were dissolved in water under constant stirring. The resulting solution was carefully transferred into a 1 mL size mold. The solution was frozen rapidly in a cold gas freezing tunnel. The water in the ice state was then removed by lyophilization to produce the fast release layer.

Table 1

Component	Example 1 (g)	Example 2 (g)	Example 3 (g)
Gelatin	1.4	1.4	1.4
Mannitol	0.9	0.9	0.9
Metronidazole	20	20	20
Neutralized 0.5% Carbopol Gel ¹	8.0	12.0	8.0
Glycine	1.0	1.0	1.0
Xanthan Gum	0.075	-	-
Water	68.6	64.7	68.7

¹ - The neutralized 0.5% carbopol gel is prepared by neutralizing carbopol with 5% w/w sodium hydroxide solution. Carbopol is available in powder form from B.F. Goodrich of Cleveland, OH.

Examples 4-12

[0042] Sustained release layers were prepared from each formulation shown in Tables 2 and 3 below as follows. Hydroxypropyl-methylcellulose, metronidazole, Wecobee FS™, and Wecobee M™ were dissolved or dispersed in

EP 1 110 541 A1

water heated to 50-70° C, under constant stirring. In some cases, the pH of solution was adjusted with lactic acid. The resulting solution was cooled to room temperature and carefully transferred into molds of various sizes. The pH, viscosity, and specific gravity (at room temperature) of the solution was determined and are shown in Tables 2 and 3. The solutions in the molds were frozen rapidly in a cold gas freezing tunnel. The water in the ice state was removed by lyophilization.

Table 2

Component	Example (weight in grams)				
	4	5	6	7	8 ⁵
Hydroxypropylmethyl cellulose ²	5	5	5	5	7
Metronidazole	12.5	12.5	12.5	12.5	12.5
Lactic Acid (pH adjuster)	-	0.1	-	0.1	-
Wecobee FS TM 3	-	-	1.4	1.4	-
Wecobee M TM 4	-	-	0.6	0.6	-
Water	82.5	82.4	80.5	82.4	80.5
Viscosity (cPs)	2000	2800	2500	2600	11000
Specific Gravity (g/mL)	1.07	1.04	1.04	1.04	1.07
pH	-	3.72	-	3.74	-
Percentage of Metronidazole in Sustained Release Layer	71%	71%	64%	64%	64%

2 - The hydroxypropylmethyl cellulose was HPMC E50LVTM available from Dow Chemical Co. of Midland, MI.

3 - Wecobee FSTM is available from Stepan Company of Northfield, IL.

4 - Wecobee MTM is available from Stepan Company of Northfield, IL.

5 - The solution in Example 8 was not lyophilized since its viscosity was so high.

Table 3

Component	Example (weight in grams)			
	9	10	11	12
Hydroxypropylmethyl cellulose ⁶	5	5	5	5
Metronidazole	25.0	25.0	25.0	25.0
Lactic Acid (pH adjuster)	-	0.1	-	0.1
Wecobee FS TM 7	-	-	1.4	1.4
Wecobee M TM 8	-	-	0.6	0.6
Water	70.0	69.9	68.0	67.9
Viscosity (cPs)	8300	6500	7400	8400
Specific Gravity (g/mL)	1.10	1.09	1.08	1.08
pH	-	3.73	-	3.70
Percentage of Metronidazole in Sustained Release Layer	83%	83%	78%	78%

6 - The hydroxypropylmethyl cellulose was HPMC E50LVTM available from Dow Chemical Co. of Midland, MI.

7 - Wecobee FSTM is available from Stepan Company of Northfield, IL.

8 - Wecobee MTM is available from Stepan Company of Northfield, IL.

Example 13

[0043] A multi-layer composition was prepared as follows. The solution of Example 9 (before freeze-drying) was dispensed, cooled to room temperature, and carefully transferred into a 1.0 mL mold. The solution of Example 1 (before freeze-drying) was then dispensed, cooled to room temperature, and carefully transferred into the mold. The weight

EP 1 110 541 A1

ratio of the solution of Example 9 to the solution of Example 1 was about 1:1. The mold and its contents were frozen rapidly in a cold gas freezing tunnel. The water in the ice state was removed by lyophilization to produce the multi-layer composition.

5 Example 14

[0044] A multi-layer composition was prepared as described in Example 13, except the solution of Example 2 was substituted for the solution of Example 1.

10 Example 15

[0045] A multi-layer composition was prepared as described in Example 13, except the solution of Example 3 was substituted for the solution of Example 1.

15 Example 16

[0046] The fast release layers, sustained release layers, and the multi-layer compositions prepared in Examples 1-7 and 9-15 were tested as follows.

[0047] The dissolution rate was determined for each release layer and composition by a modified USP type I dissolution method (United States Pharmacopeia <711>). A dialysis membrane with known molecular weight cut-off and diameter was used instead of a mesh basket for holding the test samples. The membrane limited the amount of dissolution medium which contacted the release layer or composition. This modified dissolution procedure was designed to mimic a vaginal environment where only limited amounts of a medium are typically in contact with the composition. Each release layer and composition was tested in an aqueous medium and in a buffered aqueous medium, which was maintained at a pH of about 4. The normal vaginal pH range is from about 3 to about 5. Metrogel™ available from 3M Pharmaceuticals of Northridge, CA, was also tested as described above. The results are shown in Table 4 below.

[0048] The moisture absorption of each release layer and composition was determined by measuring the percentage weight gain after storing the release layer or composition for one month at 25° C and a relative humidity of 60% and at 40° C and a relative humidity of 75%. The results are shown in Table 5 below.

Table 4

Example	Sample Size (mL)	Disintegration (75% disintegrated)	Dissolution in water (% by weight/hour)	Dissolution in buffer (% by weight /hour)
1	0.5	<1 seconds	-	29%
2	0.5	<15 seconds	-	-
3	0.5	<15 seconds	-	-
4	1.0	<20 minutes	-	14%
5	1.0	<15 minutes	-	13%
6	1.0	<2 minutes	-	13%
7	1.0	<2 minutes	-	15%
9	0.5	<11 minutes	14%	15%
10	0.5	<13 minutes	13%	11%
11	0.5	<2 minutes	-	10%
12	1.0	<2 minutes	12%	10%
13	1.0	<10 minutes ⁹	12%	18%
14	1.0	<10 minutes ⁹	-	13%
15	1.0	<10 minutes ⁹	-	10%
Metrogel™ (vaginal)	-	-	49%	55%

⁹ - The fast release layer of the compositions prepared in Examples 13-15 separated from the sustained release layer and disintegrated within about 10-15 seconds.

Table 5

Example	Sample Size (mL)	Moisture absorption at 25° C and 60% relative humidity (% w/w gain)	Moisture absorption at 40° C and 75% relative humidity (% w/w gain)
1	0.5	-	-
2	0.5	-	-
3	0.5	-	-
4	1.0	<0.1%	<2%
5	1.0	<0.1%	<5%
6	1.0	<0.1%	<2%
7	1.0	<0.1%	<2%
9	0.5	<0.1%	<2%
10	0.5	<0.1%	<1%
11	0.5	<0.1%	<4%
12	1.0	<0.1%	<1%
13	1.0	<0.1%	<1%
14	1.0	<0.1%	<1%
15	1.0	<0.1%	<1%
Metrogel™ (vaginal)	-	-	-

Example 17

[0049] A fast release layer was prepared from the formulation shown in Table 6 below as follows. Gelatin, mannitol, terconazole, carbopol, sodium hydroxide, glycine, and simethicone were dissolved in water under constant stirring. The resulting solution was carefully transferred into a 0.5 mL size mold. The solution was frozen rapidly in a cold gas freezing tunnel. The water in the ice state was then removed by lyophilization to produce the fast release layer.

Table 6

Component	% w/w
Gelatin	1.398
Mannitol	0.900
Terconazole	20.000
Carbopol	0.025
Sodium Hydroxide	0.013
Glycine	1.000
Simethicone	0.004
Water	76.600

Example 18

[0050] A sustained release layer was prepared from the formulation shown in Table 7 below as follows. Hydroxypropylmethyl cellulose and terconazole were dissolved or dispersed in water heated to 50-70° C, under constant stirring. The resulting solution was cooled to room temperature and carefully transferred into molds of various sizes. The solutions in the molds were frozen rapidly in a cold gas freezing tunnel. The water in the ice state was removed by lyophilization.

Table 7

Component	% w/w
Hydroxypropylmethyl cellulose ¹⁰	5
Terconazole	20.0
Water	75.0

¹⁰ - The hydroxypropylmethyl cellulose was HPMC E50LVTM available from Dow Chemical Co. of Midland, MI.

Example 19

[0051] A multi-layer composition was prepared as follows. The solution of Example 18 (before freeze-drying) was dispensed, cooled to room temperature, and carefully transferred into a 1.0 mL mold. The solution of Example 17 (before freeze-drying) was then dispensed, cooled to room temperature, and carefully transferred into the mold. The weight ratio of the solution of Example 18 to the solution of Example 17 was about 1:1. The mold and its contents were frozen rapidly in a cold gas freezing tunnel. The water in the ice state was removed by lyophilization to produce the multi-layer composition.

[0052] The dissolution rate of the multi-layer composition in a medium having a pH of about 4 was determined by the membrane dissolution method described in Example 16. The dissolution rate was determined to be about 50% by weight per 12 hours.

Example 20

[0053] A micro-multi-layer composition was prepared as follows. The solutions of Examples 17 and 18 (before freeze-drying) were slowly mixed at a weight ratio of about 1:1 and at a temperature of 20-45° C. The mixture was carefully transferred into 1.0 mL molds. The mold and its contents were frozen rapidly in a cold gas freezing tunnel. The water in the ice state was removed by lyophilization to produce the micro-multi-layer composition.

[0054] The dissolution rate of the micro-multi-layer composition in a medium having a pH of about 4 was determined by the membrane dissolution method described in Example 16. The dissolution rate was determined to be about 50% by weight per 10 hours.

[0055] All patents, publications, applications, and test methods mentioned above are hereby incorporated by reference. Many variations of the present matter will suggest themselves to those skilled in the art in light of the above detailed description. All such obvious variations are within the patented scope of the appended claims.

Claims

1. A composition comprising

(a) a sustained release layer comprising

(i) a water-soluble polymer, and

(ii) a first pharmaceutically active agent; and

(b) a fast release layer comprising

(i) a matrix forming agent, and

(ii) a second pharmaceutically active agent.

2. A composition as defined in claim 1, wherein the water-soluble polymer is selected from the group consisting of celluloses, cellulose ethers, polycarboxylated vinyl polymers, polyurethanes, gelatins, polysaccharide gums, seed gums, crosslinked alginate gum gels, and any combination of any of the foregoing.

3. A composition as defined in claim 2, wherein the polycarboxylated vinyl polymer is selected from the group consisting of polyacrylic acid polymers, polyacrylic acid polymers crosslinked with polyalkenyl polyethers, and any combination of any of the foregoing.

EP 1 110 541 A1

4. A composition as defined in claim 2, wherein the polysaccharide gum is selected from the group consisting of karaya gum, ghatti gum, and combination of any of the foregoing.
5. A composition as defined in claim 2, wherein the seed gum is selected from the group consisting of guar gum, locust bean gum, psyllium seed gum, and any combination of any of the foregoing.
6. A composition as defined in claim 2, wherein the water-soluble polymer is selected from the group consisting of polyurethanes, gelatins, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose, hydroxypropylethylcellulose, carbopol, polyvinyl alcohol, dextran, chitosan, starches, polyacrylamides, polyacrylates, agar, collagen, fibronectin, alginic acid, pectin, hyaluronic acid, and any combination of any of the foregoing.
7. A composition as defined in claim 1, wherein the sustained release layer further comprises (iii) a fatty acid.
8. A composition as defined in claim 1, wherein the fatty acid is a hydrogenated vegetable oil.
9. A composition as defined in claim 1, wherein the first pharmaceutically active agent is selected from the group consisting of an anti-fungal agent, an anti-bacterial agent, a nutrient, a vitamin, a mineral, a diagnostic, a fertilizer, an insecticide, or any combination of any of the foregoing.
10. A composition as defined in claim 1, wherein the first pharmaceutically active agent is selected from the group consisting of metronidazole, miconazole nitrate, terconazole, chlorpheniramine maleate, pseudophedrine, dextromethorphan, meclizine dihydrochloride, haloperidol, albuterol sulfate, dimenhydrinate, benzodiazepines, and any combination of any of the foregoing.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 31 1631

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 93 02662 A (L C PHARCHEM LTD) 18 February 1993 (1993-02-18) * page 1, line 1 - page 1, line 2 * * page 4, line 5 - page 4, line 12 * * example 4 *	1-10	A61K9/19
X	--- CHEMICAL ABSTRACTS, vol. 127, no. 22, 1 December 1997 (1997-12-01) Columbus, Ohio, US: abstract no. 311405, IWATA, MASANORI ET AL: "Sustained-release double-layered progesterone suppository for luteal - support therapy" XP002162841 * abstract * & YAKUGAKU ZASSHI (1997), 117(9), 629-635	1-10	
X	--- US 4 915 953 A (JORDAN MAUREEN L ET AL) 10 April 1990 (1990-04-10) * column 1, line 19 - column 1, line 30 * * column 8, line 3 * * example 1 *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K
X	--- US 6 004 582 A (MAYORGA JORGE ET AL) 21 December 1999 (1999-12-21) * examples 2,4 *	1-10	
X	--- EP 0 220 670 A (EISAI CO LTD) 6 May 1987 (1987-05-06) * examples 1-4 *	1-10	
X	--- WO 99 33448 A (MERCK PATENT GMBH ; SASLAWSKI OLIVIER (FR); ORLANDO LAURENCE (FR)) 8 July 1999 (1999-07-08) * example 1 *	1-10	
		-/-	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 14 March 2001	Examiner Borst, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503/01 (P/AC01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 31 1631

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 4 122 157 A (HUBER HAROLD E) 24 October 1978 (1978-10-24) * examples 1-4 *	1-10	
X	US 5 085 865 A (NAYAK AMMUNJE S) 4 February 1992 (1992-02-04) * example 1 *	1-10	
X	EP 0 090 997 A (RUHLAND NACHF GMBH DR) 12 October 1983 (1983-10-12) * page 7, line 6 - page 7, line 17 * * page 8, line 1 - page 8, line 20 *	1	
A	US 5 891 458 A (FLANAGAN PATRICIA ET AL) 6 April 1999 (1999-04-06) * column 1, line 18 - column 1, line 30 *	1-10	
A	EP 0 747 045 A (ORTHO PHARMA CORP) 11 December 1996 (1996-12-11) * page 1, line 45 - page 1, line 50 *	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 14 March 2001	Examiner Borst, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on or after the filing date O : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPIC FORM 1503 (2.9.96) (Rev. 01/01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 31 1631

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-03-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9302662	A	18-02-1993	IT 1251114 B	04-05-1995
			AT 129149 T	15-11-1995
			AU 2345492 A	02-03-1993
			CA 2114216 A	18-02-1993
			DE 69205579 D	23-11-1995
			DE 69205579 T	04-04-1996
			DK 596935 T	22-01-1996
			EP 0596935 A	18-05-1994
			JP 6509348 T	20-10-1994
US 4915953	A	10-04-1990	US 4814181 A	21-03-1989
			AT 400296 B	27-11-1995
			AT 214488 A	15-04-1995
			AU 2152688 A	09-03-1989
			BE 1001184 A	08-08-1989
			CA 1288016 A	27-08-1991
			CH 676794 A	15-03-1991
			DE 3829942 A	16-03-1989
			DK 485588 A	04-03-1989
			ES 2008580 A	16-07-1989
			FI 884056 A	04-03-1989
			FR 2620025 A	10-03-1989
			GB 2209280 A, B	10-05-1989
			IE 61845 B	30-11-1994
			IT 1223798 B	29-09-1990
			JP 1096116 A	14-04-1989
			KR 9506216 B	12-06-1995
			LU 87326 A	08-03-1989
			NL 8802180 A	03-04-1989
			NO 176902 B	13-03-1995
			PT 88404 A, B	31-07-1989
			SE 8803084 A	04-03-1989
			US 4915954 A	10-04-1990
			ZA 8806435 A	30-05-1989
US 6004582	A	21-12-1999	AU 7706598 A	30-12-1998
			BR 9802144 A	25-05-1999
			CA 2261787 A	03-12-1998
			CN 1228020 T	08-09-1999
			EP 0914098 A	12-05-1999
			WO 9853802 A	03-12-1998
			JP 2000516637 T	12-12-2000
EP 0220670	A	06-05-1987	JP 1713820 C	27-11-1992
			JP 3027529 B	16-04-1991
			JP 62103012 A	13-05-1987

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 31 1631

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-03-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0220670	A		AT 84212 T	15-01-1993
			DE 3687442 A	18-02-1993
			DE 3687442 T	03-06-1993
			DK 498886 A	24-04-1987
			KR 9104577 B	06-07-1991
			NO 864243 A, B,	24-04-1987
			US 5093200 A	03-03-1992
WO 9933448	A	08-07-1999	FR 2772615 A	25-06-1999
			AU 2160699 A	19-07-1999
			BR 9814345 A	03-10-2000
			CN 1283110 T	07-02-2001
			EP 1041972 A	11-10-2000
			NO 20003289 A	22-08-2000
			ZA 9811799 A	22-06-1999
US 4122157	A	24-10-1978	AU 510924 B	17-07-1980
			AU 3260278 A	26-07-1979
			BE 864349 A	16-06-1978
			CA 1090254 A	25-11-1980
			DE 2808514 A	07-09-1978
			FR 2382235 A	29-09-1978
			GB 1551698 A	30-08-1979
			IL 53851 A	16-09-1980
			JP 53109932 A	26-09-1978
			NL 7801187 A	06-09-1978
			PH 14916 A	29-01-1982
			ZA 7800269 A	31-01-1979
US 5085865	A	04-02-1992	AU 639231 B	22-07-1993
			AU 5314490 A	18-10-1990
			CA 2014418 A	12-10-1990
			GB 2230185 A, B	17-10-1990
			NZ 231247 A	25-09-1991
			ZA 9002792 A	30-01-1991
EP 0090997	A	12-10-1983	DE 3212412 A	13-10-1983
			AT 47317 T	15-11-1989
			DE 3380727 D	23-11-1989
			JP 1636531 C	31-01-1992
			JP 2060339 B	17-12-1990
			JP 58185162 A	28-10-1983
US 5891458	A	06-04-1999	US 5458884 A	17-10-1995
			CA 2105887 A	11-03-1994
			EP 0643963 A	22-03-1995

EP FORM P448

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 31 1631

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-03-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5891458 A		NO 933239 A	04-05-1994
		NZ 299162 A	27-05-1998
		US 5650192 A	22-07-1997
		ZA 9306711 A	10-03-1995
EP 0747045 A	11-12-1996	US 5656283 A	12-08-1997
		AU 714230 B	23-12-1999
		AU 5582696 A	19-12-1996
		AU 6334596 A	09-01-1997
		BR 9602703 A	22-04-1998
		CA 2178566 A	09-12-1996
		JP 9103467 A	22-04-1997
		NO 962423 A	09-12-1996
		NZ 286745 A	24-06-1997
		WO 9641615 A	27-12-1996

EPO FORM PC/457

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant:

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)